Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of hiPSC-derived cardiomyocytes to study LQTS-variant specific proarrhythmic effects of drugs.

Vascular pharmacology - 1 Jun 2024

Sala Luca, Khudiakov Aleksandr, Mura Manuela, Leonov Vladislav, Giannetti Federica, Crotti Lia, Gnecchi Massimiliano, Schwartz Peter J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Heart Rate
Share to Induced Pluripotent Stem Cells
Share to Long QT Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myocytes, Cardiac

Share to Pharmacogenomic Variants

Share to Phenotype

Source

Identifiers

PMID: 38985625
DOI: 10.1016/j.vph.2024.107347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of hiPSC-derived cardiomyocytes to study LQTS-variant specific proarrhythmic effects of drugs.PMID 38985625Read ↗

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce ToxicitySemantic proximity Read ↗

Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and LimitationsSemantic proximity Read ↗

Characteristics and pharmacological responsiveness in hiPSC models of inherited cardiomyopathy.Semantic proximity Read ↗

Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.Semantic proximity Read ↗

Human Engineered Heart Tissue Models for Disease Modeling and Drug DiscoverySemantic proximity Read ↗

Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmiasSemantic proximity Read ↗

Induced pluripotent stem-cell-derived cardiomyocytes: cardiac applications, opportunities, and challenges.Semantic proximity Read ↗

iPSC-Derived Cardiomyocytes in Inherited Cardiac Arrhythmias: Pathomechanistic Discovery and Drug DevelopmentSemantic proximity Read ↗

The Emergence of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform to Model Arrhythmogenic DiseasesSemantic proximity Read ↗

Induced Pluripotent Stem Cell–Derived CardiomyocytesSemantic proximity Read ↗

Long QT Syndrome modelling with cardiomyocytes derived from human-induced pluripotent stem cellsSemantic proximity Read ↗

Induced Pluripotent Stem Cells in Congenital Long QT Syndrome: Research Progress and Clinical ApplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.